Leadership
Our goal
All SMART-C activities are overseen by a Steering Committee comprised of the 23 leaders of completed SGLT2 inhibitor outcome trials. The Steering Committee is responsible for overall scientific leadership of the Consortium, and convenes regularly to review and discuss specific research proposals and prioritizes projects based on clinical importance, feasibility, and data availability.
Dr Brendon L Neuen
The George Institute for Global Health, University of New South Wales, Australia
Professor Hiddo JL Heerspink
Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Netherlands, and The George Institute for Global Health, University of New South Wales, Australia
Professor Stefan D Anker
Department of Cardiology (CVK) of German Heart Center Charité; Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin, Germany
Professor Deepak L Bhatt
Mount Sinai Heart, USA
Professor Javed Butler
Baylor Scott and White Research Institute, USA
Professor David Z Cherney
Toronto General Research Institute, University Health Network, University of Toronto, Canada
Professor Will Herrington
Nuffield Department of Population Health, University of Oxford, UK
Professor Silvio E Inzucchi
Yale University School of Medicine, USAaYale University School of Medicine, USA
Professor Meg Jardine
NHMRC Clinical Trials Centre, University of Sydney, Australia
Professor Kenneth W Mahaffey
Stanford Center for Clinical Research, Department of Medicine, Stanford University, USA
Professor Darren K McGuire
University of Texas Southwestern Medical Center, USA
Professor John JV McMurray
School of Cardiovascular and Metabolic Health, University of Glasgow, UK
Professor Bruce Neal
The George Institute for Global Health, University of New South Wales, Australia
Professor Milton Packer
Baylor University Medical Center, USA and Imperial College London, UK
Professor Vlado Perkovic
The George Institute for Global Health, University of New South Wales, Australia
Professor Marc S Sabatine
TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, USA
Professor Scott Solomon
Brigham and Women’s Hospital, Harvard Medical School, USA
Associate Professor Natalie Staplin
Nuffield Department of Population Health, University of Oxford, UK
Dr Muthiah Vaduganathan
Brigham and Women’s Hospital, Harvard Medical School, USA
Professor Christoph Wanner
University Hospital of Würzburg, Germany
Professor Stephen D Wiviott
TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, USA
Professor David C Wheeler
Department of Renal Medicine, University College London, UK
Emeritus Professor Faiez Zannad
Université de Lorraine, Inserm and CHRU de Nancy, France
